Protocols for drug allergy desensitization in children

Expert Rev Clin Immunol. 2020 Jan;16(1):91-100. doi: 10.1080/1744666X.2019.1698294. Epub 2019 Dec 8.

Abstract

Introduction: When a drug hypersensitivity reaction is proven, desensitization protocols allow the reintroduction of the molecule in patients for whom such therapy is essential. Through drug desensitization (DDS), a temporary immune tolerance is maintained for the single course of a specific therapy. In pediatrics, indications for such a procedure include children with chronic diseases, severe infectious diseases and/or malignancies, who have a proven drug hypersensitivity.Areas covered: We ran a search on PubMed and Web of Science for papers on DDS and on DDS in children. Most protocols and recommendations on DDS focus on adults and have been adapted for children. The best candidates for desensitization are children with a history of immediate, IgE-mediated drug allergy, but this therapy may be applied also in nonallergic hypersensitivities and in non-immediate reactions. Most protocols in literature focus on antibiotics, especially beta-lactams, on chemotherapeutic agents, and on monoclonal antibodies.Expert opinion: Pediatric allergists should cooperate with specialists in infectious diseases and onco-hematology to provide DDS to children in need. Standardized protocols and international guidelines are still needed to optimize such treatment and to implement it in clinical daily practice.

Keywords: Antibiotics; chemotherapeutic agents; children; drug allergy; drug desensitization; monoclonal antibodies; pediatrics; protocols.

Publication types

  • Review

MeSH terms

  • Allergens / immunology
  • Anti-Bacterial Agents / immunology
  • Antibodies, Monoclonal / immunology
  • Antineoplastic Agents / immunology
  • Child
  • Clinical Protocols
  • Desensitization, Immunologic / methods*
  • Drug Hypersensitivity / immunology
  • Drug Hypersensitivity / therapy*
  • Humans
  • Immune Tolerance

Substances

  • Allergens
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antineoplastic Agents